Profile picture of Alison Hadley

Dr Alison Hadley

Profile picture of Alison Hadley

MBBS (Hons), FRACP

Medical Oncologist
Call
Referrals

Dr Alison Hadley advocates for her patients during every step of their cancer journey, delivering compassionate care with an emphasis on open communication and collaboration. Her evidence-based practice ensures that her patients receive the highest clinical standards, including detailed and diligent clinical assessments.

Biography

Dr Alison Hadley is an experienced medical oncologist at Icon Cancer Centre Hobart. In 1999 she completed her Bachelor of Medicine, Bachelor of Surgery (MBBS) with Honours and became a medical oncology fellow at the Royal Australasian College of Physicians (FRACP) in 2007. She subsequently completed a Master of Medicine (Clinical Epidemiology) in 2010. She is a member of several professional organisations, including the American Society of Clinical Oncology, Australia New Zealand Gynaecologic Oncology Group (ANZGOG), Australia New Zealand Urological Cancer Group (ANZUP), and Australasian Gastrointestinal Trials Group (AGITG).

She is deeply interested in clinical research and cancer genetics and maintains research affiliations with several national and international institutions. She conducts thorough and meticulous clinical assessments and offers personalised advice to ensure the best possible care for all her patients. Dr Hadley also practices at Hobart Private Hospital and Calvary St John’s/Lenah Valley Hospitals.

Dr Hadley is available for initial consultations and second opinions and is dedicated to her practice and clinical research. Her clinical experience covers a broad range of solid tumour malignancies with a special interest in breast cancer, gynaecological cancer, colorectal cancer, urogenital cancer, and has a particular interest in clinical research and cancer genetics.

Publications

    • Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.  Mod Pathol. 2021 Jan;34(1):194-206. 

    Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study, DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators (A Hadley).

    • Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020 Mar;156(3):552-560

    Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.

    • NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.  Journal of Clinical Oncology 2020 38:15_suppl, 103-103.

    Damien Kee, Olga Kondrashova, Sumitra Ananda, Michael Paul Brown, Paul Andrew Cohen, Andrew Dean, Jayesh Desai, Andrew Fellowes, Stephen B. Fox, Alison Hadley, Dianne Lindsay, Linda R. Mileshkin, Kenneth John O’Byrne, Owen W.J. Prall, Hamish Scott, David Morgan Thomas, Richard Vines, Nic Waddell, Anthony Papenfuss, and Clare L. Scott

    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018 Sep 28;9(1):3970.

    Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

    • Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2017 (5):900-906.

    Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators.  Paragon (ANZGOG-0903)

Special Interests

Dr Alison Hadley accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Colorectal cancer
  • Genitourinary cancer
  • Gynaecological cancer

Languages spoken

  • English

Icon Locations

Affiliations & Memberships

  • Royal Australasian College of Physicians (RACP)
  • Australia New Zealand Gynaecologic Oncology Group (ANZGOG)
  • Australia New Zealand Urological Cancer Group (ANZUP)
  • Australasian Gastrointestinal Trials Group (AGITG)
  • American Society of Clinical Oncology
  • European Society of Clinical Oncology

Publications

    • Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.  Mod Pathol. 2021 Jan;34(1):194-206. 

    Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study, DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators (A Hadley).

    • Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020 Mar;156(3):552-560

    Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.

    • NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.  Journal of Clinical Oncology 2020 38:15_suppl, 103-103.

    Damien Kee, Olga Kondrashova, Sumitra Ananda, Michael Paul Brown, Paul Andrew Cohen, Andrew Dean, Jayesh Desai, Andrew Fellowes, Stephen B. Fox, Alison Hadley, Dianne Lindsay, Linda R. Mileshkin, Kenneth John O’Byrne, Owen W.J. Prall, Hamish Scott, David Morgan Thomas, Richard Vines, Nic Waddell, Anthony Papenfuss, and Clare L. Scott

    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018 Sep 28;9(1):3970.

    Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

    • Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2017 (5):900-906.

    Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators.  Paragon (ANZGOG-0903)

Search

Contact us
Become a patient